When was Aura Biosciences founded?

Aura Biosciences was founded in 2007 and raised its 1st funding round 3 years after it was founded.

Where is Aura Biosciences located?

Aura Biosciences is headquartered in Cambridge, United States. It is registered at FLAT NO 4 JEEVAN ADHAR CO OPHSG SOC MAHANT ROAD VILE PARLE EAST, MUMBAI, Maharashtra, India, 400057.

Who is the current CEO of Aura Biosciences?

Elisabet de los Pinos of Aura Biosciences.

How many employees does Aura Biosciences have?

As of Jun 30, 2026, the latest employee count at Aura Biosciences is 129.

Is Aura Biosciences a funded company?

Aura Biosciences is a funded company, having raised a total of $215M across 11 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Sep 21, 2010.

When was the latest funding round of Aura Biosciences?

Aura Biosciences' latest funding was a $***** Series D round on Mar 22, 2021, with participation from 12 investors.

Where does Aura Biosciences rank among its competitors?

Aura Biosciences ranks 161st amongst 3733 active competitors, of which 1298 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Aura Biosciences?

Aura Biosciences' top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

Aura Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Provider of therapies to target and destroy cancer cells. Its lead candidate is for the treatment of ocular (uveal) melanoma. It consists of a viral-like particle conjugated to an infra-red activated small molecule. It binds selectively to cancer cells in the eye and upon activation with an ophthalmic laser, the small molecule selectively destroys the membrane of cancer cells, killing them without damaging the overlying retina.

Website: www.aurabiosciences.com/
Social
Registered Address: FLAT NO 4 JEEVAN ADHAR CO OPHSG SOC MAHANT ROAD VILE PARLE EAST, MUMBAI, Maharashtra, India, 400057

Key Metrics

Founded Year

2007

Location

Cambridge, United States

Stage

Public

Total Funding

$215M in 11 rounds

Latest Funding Round

Series D, Mar 22, 2021, $*****

Investors

Advent International & 21 more

Ranked

161^st among 3733 active competitors

Employee Count

129 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3564 more

Exit Details

Public

View Aura Biosciences' full profile

Aura Biosciences is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AURA BIOSCIENCES, INC. CIN: 32-0271970 , United States, Active	Jan 12, 2009	-	52 (As on Feb 28, 2022)	-
AURA LIFE SCIENCES PRIVATE LIMITED CIN: U24230MH2004PTC149605 , India, Active	Nov 19, 2004	₹10 - ₹50 Cr (As on Mar 31, 2025)	-
Aura Biosciences, Inc. CIN: 20211827633 , United States, Active	Sep 07, 2021	-	-	-

Aura Biosciences got listed on Oct 29, 2021.

Click here to take a look at Aura Biosciences's IPO in detail

Aura Biosciences has raised a total funding of $215M over 11 rounds. Its first funding round was on Sep 21, 2010. Its latest funding round was a Series D round on Mar 22, 2021 for $*****. 12 investors participated in its latest round. Aura Biosciences has 21 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Aura Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 22, 2021	8610941	Series D	3556508	6068645	9289879	5855975
Jul 09, 2020	8402629	Series D	8631130	4540157	5669286	4256309
Apr 12, 2019	6518754	Series D	3356634	7396174	Medicxi	Arix Bioscience & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Aura Biosciences's funding rounds and investors

The founders of Aura Biosciences is Elisabet de los Pinos.

Here are the details of Aura Biosciences' key team members:

Elisabet de los Pinos: Founder and CEO of Aura Biosciences.

View details of Aura Biosciences's Founder profiles and Board Members

Aura Biosciences' employee count trend

Aura Biosciences has 129 employees as of Jun 26. Here is Aura Biosciences's employee count trend over the years:

Employee count trend for Aura Biosciences

Uncover Aura Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aura Biosciences include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Aura Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
161st	Aura Biosciences 2007, Cambridge (United States), Public	Provider of therapies to target and destroy cancer cells	$215M	Lundbeck Foundation, Advent Life Sciences ... & 20 others	62/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Aura Biosciences's competitors? Click here to see the top ones

Aura Biosciences has made no investments or acquisitions yet.

Here is the latest report on Aura Biosciences's geography:

Free

US Fintech Quarter Funding Report

Edition: Quarter 1, 2026 (41 Pages)

View all reports related to Aura Biosciences

Media has covered Aura Biosciences for a total of 12 events in the last 1 year, 5 of them have been about company updates and 2 about people movement.